Pantoprazol Accord (Pantoprazole)

Pantoprazole blocks the H+/K+‑ATPase enzyme, commonly called the gastric proton pump, on the surface of stomach parietal cells. By inhibiting this final step of acid secretion, it raises gastric pH and reduces the amount of acid that reaches the oesophagus and duodenum.

The prescribed dose of Pantoprazol Accord is determined by the treating clinician based on the patient’s condition, severity and response to therapy. Dosage recommendations are provided in the product’s prescribing information and should be followed as directed by a healthcare professional.

Pantoprazole is classified as pregnancy category B in many regions, indicating no evidence of risk in animal studies but limited human data. It should be used during pregnancy or lactation only if the potential benefit justifies any potential risk, and the decision should be made by the prescribing physician.

To place an order, submit an enquiry on the Pantoprazol Accord product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Pantoprazol Accord belongs to the proton pump inhibitor class, which generally provides more potent and longer‑lasting acid suppression than H2‑receptor antagonists such as ranitidine. Compared with other PPIs, pantoprazole has a lower potential for drug‑drug interactions mediated by CYP2C19, making it a suitable option for patients on multiple medications.

Store Pantoprazol Accord tablets at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain tablet integrity.

Pantoprazol Accord is taken orally, usually as a whole tablet with a glass of water. It can be taken with or without food, but consistency in timing relative to meals helps maintain stable drug levels. Patients should follow the prescribing clinician’s instructions regarding frequency and duration.

Serious adverse events, although rare, include severe allergic reactions, Clostridioides difficile‑associated diarrhoea, low magnesium levels, liver enzyme elevations and an increased risk of bone fractures with long‑term use. Any signs of these conditions should prompt immediate medical evaluation.

Pantoprazol Accord is contraindicated in patients with known hypersensitivity to pantoprazole or any other component of the formulation. Caution is also advised for individuals with severe hepatic impairment, as exposure may be increased. Clinicians should assess each patient’s medical history before initiating therapy.